摘要
目的:探讨阿托伐他汀联合阿加曲班治疗缺血性脑卒中患者对的临床效果及对FIB、PT、APTT的影响。方法:选取2017年8月-2019年10月本院收治的96例缺血性脑卒中患者为研究对象,按随机数字表法将其分为对照组与研究组,每组48例。对照组应用阿托伐他汀治疗,研究组应用阿托伐他汀联合阿加曲班治疗。比较两组治疗前后凝血功能、肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)、乳酸、超敏C反应蛋白(hs-CRP)、美国国卫院脑卒中评估表(national institute of health stroke scale,NIHSS)评分、Barthel指数及治疗效果。结果:治疗后,研究组凝血酶原时间(PT)与活化部分凝血活酶时间(APTT)均高于对照组,而纤维蛋白原(FIB)低于对照组(P<0.05);治疗后,研究组TNF-α与IL-6水平均低于对照组(P<0.05);治疗后,研究组乳酸与hs-CRP水平均低于对照组(P<0.05);治疗后,研究组NIHSS评分低于对照组,而Barthel指数高于对照组(P<0.05);研究组治疗总有效率高于对照组(P<0.05)。结论:阿托伐他汀联合阿加曲班治疗缺血性脑卒中患者的效果理想,能够有效改善患者的凝血功能,进而改善神经功能的缺损,临床上应当进一步推广应用。
Objective:To investigate the clinical effect of Atorvastatin combined with Argatroban in the treatment of patients with ischemic stroke and its effect on FIB,PT and APTT.Method:A total of 96 patients with ischemic stroke admitted to our hospital from August 2017 to October 2019 were selected as the research objects.They were divided into control group and research group according to random number table method,with 48 cases in each group.The control group was treated with Atorvastatin,and the research group was treated with Atorvastatin combined with Argatroban.Coagulation function,tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),lactic acid,hypersensitive C reactive protein(hs-CRP),national institute of health stroke scale(NIHSS)score,Barthel index before and after treatment and treatment effect were compared between the two groups.Result:After treatment,the prothrombin time(PT)and activated partial thromboplastin time(APTT)in the study group were higher than those in the control group,while the fibrinogen(FIB)was lower than that in the control group(P<0.05).After treatment,the levels of TNF-αand IL-6 in the study group were lower than those in the control group(P<0.05).After treatment,the levels of lactic acid and hs-CRP in the study group were lower than those in the control group(P<0.05).After treatment,NIHSS score of the study group was lower than that of the control group,while Barthel index was higher than that of the control group(P<0.05).The total effective rate of study group was higher than that of control group(P<0.05).Conclusion:Atorvastatin combined with Argatroban has an ideal effect in the treatment of patients with ischemic stroke,which can effectively improve the coagulation function of patients and thus improve the neurological function defect,and should be further promoted and applied in clinical practice.
作者
李克颖
李莹
LI Keying;LI Ying(Jiamusi Central Hospital,Jiamusi 154002,China;不详)
出处
《中国医学创新》
CAS
2021年第4期1-5,共5页
Medical Innovation of China